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Abbreviations 
ARC Adenosine analogue and peptide conjucates   
ATP Adenosine-5'-triphosphate 
Abu γ-aminobutyl acid 
Boc tert-butoxycarbonyl 
DCE 1,2-dichloroethane 
DMF N,N-dimethylformamide 
DMSO Dimethyl sulfoxide 
CX-4945 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid 
Fmoc 9-fluorenylmethyloxycarbonyl chloride 
HBTU O-Benzotriazole-N,N,N’,N’-tetramethyl-uronium-hexafluoro-phosphate 
HOBt 1-hydroxybenzotriazole 
HPLC High performance liquid chromatography 
KOtBu Potassium tert-butoxide 
MALDI-TOF Time of flight matrix-assisted laser desorptsion/ionisation 
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NMM N-methylmorpholine  
SPPS Solid phase peptide synthesis 
TBBI 4,5,6,7-tetrabromobenzimidazole 
TFA Trifluoroacetic acid 
TIPS Triisopropylsilane  
TLC Thin layer chromatography 
NMR Nuclear magnetic resonance spectroscopy   
UV-VIS Ultravioletse ja nähtava ala spektroskoopia 
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1. Introduction 
Protein kinase CK2 is a highly conserved and acidophilic serine/threonine type of protein 
kinase. It is expressed in eukaryotic cells at high concentration. Like other protein kinases, 
CK2 catalyses the transfer of the ATP terminal phosphoryl group to a protein substrate. 
Increased activity of CK2 is related to many different diseases, such as various types of 
cancers, Alzheimer’s disease, diabetes, inflammation. That is why it is important to research 
CK2 inhibitors as potential drugs against diseases caused by increased activity of the enzyme. 
Most of CK2 inhibitors are ATP-competitive. Since these inhibitors are binding only one 
active site of the enzyme, they often have low selectivity or affinity. 
The aim of this study was to develop new, highly selective and affine bisubstrate inhibitors 
for CK2. Highly selective and affine inhibitors and their fluorescent probes can be useful 
probes for studying CK2 and its ligands. These applications include monitoring of CK2 
location in cells, quantification of CK2 in samples, screening of new inhibitors, 
co-crystallisation. Tight-binding bisubstrate inhibitors could simplify the research of the 
protein binding site of CK2. Currently, the ATP binding site and its interactions are well 
studied, but there is lack of information about the mechanism and interactions between 
protein substrate and its binding site. High affinity bisubstrate inhibitors could help determine 
the characteristics of the binding site, which would give new information about functioning of 
CK2 and aids the development of new CK2 inhibitors. In addition, high affinity fluorescent 
probes can be used to determine the inhibition activity of new high affinity bisubstrate 
inhibitors.  
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2. Literature overview 
2.1. Protein kinases 
Protein kinases catalyse a simple, yet important reaction: the transfer of the terminal (also 
known as gamma) phosphoryl group of nucleotide (for example ATP or GTP) to the hydroxyl 
group of an amino acid residue (serine, threonine or tyrosine) of a protein/peptide substrate 
(Scheme 1). [1] 
Protein kinases are scientifically interesting biological catalytic enzymes, which have a very 
important role in the life cycle of cells [1]. They belong to the transferase class of enzymes 
[2]. Because of the importance of phosphorylation, the activity of protein kinases influences 
most signalling pathways, affecting viability, movements, substance transport and 
proliferation. [1] 
 
Scheme 1. Transfer of terminal phosphoryl group of ATP to amino acid residue hydroxyl 
group. [1] 
As of 2011, there are 538 known protein kinases. Ninety of those kinases transfer the 
phosphoryl group to tyrosine residue, but the majority kinases of human genome are 
serine/threonine kinases. [1] 
Because of protein kinases important role in cell growth, proliferation and death regulation, 
increased activity of protein kinases is related to different diseases, such as diabetes, 
Alzheimer’s disease, inflammation and various types of cancer. This is the reason why many 
protein kinases are target molecules in drug development. [2] 
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2.2 Protein kinase CK2 
Protein kinase CK2 is a highly conserved serine/threonine type protein kinase usually 
presented in cells as a tetramer, containing two catalytic subunits (α or α’, expressed by 
different genes) and two regulatory subunits (β). CK2 is always found to be active and 
ubiquitously expressed. [3] The regulatory subunit does not regulate the overall activity of the 
catalytic subunit, but stabilises the formation of holoenzyme and affects the activity toward 
some peptide substrates, which are CK2β dependent. There is not complete understanding of 
the roll of the regulatory subunit. [4] There are more than 300 peptide substrates of CK2, and 
because of that it is considered to be the most pleiotropic protein kinase. [5] 
 
Figure 1. Crystal structure of CK2 holoenzyme. Catalytic subunits are coloured green and 
cyan; regulatory subunits are coloured yellow and magneta. (PDB code: 1JWH) 
Such a large number of substrates indicate that CK2 is involved in many important cellular 
processes. [5] It is found to be a regulating enzyme for gene expression, cell growth, cell 
cycle and anti-apoptosis. [6] 
CK2 plays an important role in tumorigenesis and is related to various types of cancers 
(leukaemia, neck, lung, breast, kidney and prostate cancer [7]), because CK2 is found to be 
over expressed and highly active in cancer cells, compared to healthy ones. It also seems that 
the cancer cells are relying more on CK2 than normal cells; therefore, inhibition of CK2 
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activity influences tumour cells more. This phenomenon is called CK2 “addiction”. Because 
of these reasons, CK2 is considered an important target-protein in drug development. [3] 
2.3. Protein kinase inhibitors 
There are four types of protein kinase inhibitors. ATP-competitive inhibitors bind to the ATP 
binding site of the enzyme. Peptide-substrate competitive inhibitors bind to the peptide-
substrate binding site of the kinase. There are bisubstrate inhibitors, which bind both binding 
sites at the same time, increasing the affinity and selectivity of the inhibitor. The fourth type 
of inhibitors are called allosteric inhibitors, which do not bind to an active site, but some other 
place on the kinase, changing the conformation of the enzyme and making it inactive. 
Allosteric inhibitors are rare. 
The majority of protein kinase inhibitors are ATP-competitive. They usually have good 
affinity but poor selectivity because of the high homology of ATP-binding sites. There are 
some highly selective peptide-substrate inhibitors. However, high affinity peptide-substrate 
competitive inhibitors need to be longer, which make their cellular transport and stability a 
problem. [2] 
2.3.1. Inhibitors of protein kinase CK2 
Among protein kinase inhibitors, most of the known CK2 inhibitors are ATP-competitive. [8] 
In addition to the fact that the abnormality of CK2 activity causes serious health problems, 
there are two main reasons why CK2 is a good target protein. Firstly, signal pathways do not 
rely on CK2, but it is a modulator protein of them, hence adult organisms will cope more 
easily with its inhibition. Secondly, CK2 has a smaller ATP binding-site than other protein 
kinases, which helps to design selective and low molecular weight inhibitors. [9] 
In the field of ATP-competitive inhibitors for CK2, different types of selective inhibitors have 
been discovered. [8] For example, many halogenated benzimidasoles have been researched as 
potential selective CK2 inhibitors, but their affinities toward CK2 were around micro molar 
range [10]. Also natural substances, for instance some flavonoids (e.g. quercetine) are found 
to be inhibitors for CK2. Their best inhibition activities were around sub-micromolar range. 
[11] In 2011, a new selective and subnanomolar affinity inhibitor was reported. It was named 
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CX-4945. It was also the first CK2 inhibitor to be taken into clinical trials as a potential 
treatment for cancer. [12] 
 
 
Scheme 2. Structure of CX-4945 
2.4. Bisubstrate kinase inhibitors 
Bisubstrate inhibitors consist of two fragments, each targeting one of the protein kinase 
substrate binding-sites. The two fragments are attached to each other with a hydrophobic 
linker. Since both inhibitor parts are developed to inhibit the binding site of a distinct 
substrate, with optimal linker length, bisubstrate inhibitors are potentially highly selective and 
affine toward the target enzyme. [2] 
There are many types of bisubstrate inhibitors for protein kinase. They vary by the ATP-
competitive part (adenosine or adenosine mimic can be used) and the peptide-substrate 
competitive fragment (different peptide sequences can be used). The type and length of the 
linker between two fragments is modified to reach the optimal characteristic. [2] 
2.4.1 Bisubstrate inhibitors of protein kinase CK2 
Several ATP-competitive inhibitors have been developed for CK2, but other types of 
inhibitors have found less interest. Based on writer’s bachelor thesis, an article has been 
published, reporting a high affinity bisubstrate inhibitor for CK2. [13] Before that, only one 
attempt to design biligand inhibitors that resulted with micromolar inhibitory potency has 
been published. [14] 
The reported affinities of the novel subnanomolar compounds published in [13] reached 0.5 
nM. In comparison, the affinity of CX-4945 is in the same magnitude. Since many protein 
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kinases are basophilic, the acidic bisubstrate inhibitors have high selectivity toward CK2 
because of its acidophilic characteristics. Because of the high selectivity and affinity toward 
the CK2, bisubstrate inhibitors and their fluorescent probes can be used for detecting the 
concentration of the kinase, studying interactions of CK2 with other proteins, and they are 
potential drugs against cancer. [13] 
Even though there is information about the interactions of the adenosine binding-site of CK2, 
there are still no crystal structure data of peptide substrate binding with its binding site on the 
CK2. High affinity bisubstrate inhibitors are potentially useful tools for that because of their 
tight binding to the CK2, which potentially makes the binding peptide part more stabilized, 
than the usual peptide substrate and thus more easily recognizable in X-ray crystallography. 
Enzyme interactions with the peptide substrate would help us to understand the binding 
mechanisms and characteristics of CK2 protein binding site. [13] 
 
Figure 2. Structure of the fluorescent probe of CK2 bisubstrate inhibitor ARC-1502 (ARC-
1504). [13] 
2.5. Electrophilic substitution in aromatic ring 
Electrophilic aromatic substitution reactions are very important, well-studied organic 
synthesis reactions. Most substitutions at an aliphatic carbon are nucleophilic, but in the case 
of aromatic compounds, it is electrophilic. That is because of the high electron density at the 
aromatic ring that leads its reactivity as Lewis base or Brønsted-Lowry base. [15]  
A wide variety of electrophiles can attack the aromatic ring and effect substitution. There are 
compounds, which can substitute the aromatic ring without any prior activation of the ring. 
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On the other hand, there are substituents that can only react with an activated aromatic ring. In 
addition, the scale and position of substitution can be manipulated by using different 
substituents, activators or previously substituted aromatic compounds. [16] 
 
E-Y
E
+ H-Y
H
H
E :Y
+
 
Scheme 3. General mechanism of electrophilic substitution. 
2.5.1. Halogenation 
Halogenation is a very common electrophilic substitution used in organic synthesis. There are 
different methods and reagents used for this reaction. The reactivity of halogens grow in order 
I2<Br2<Cl2<F2, F2 being to most reactive. [16] 
Reaction with fluorine does not need any catalyst, because it reacts so rapidly, and for that 
synthesis special lab equipment is needed. For bromination and chlorination, usually a Lewis 
acid is used as a catalyst to achieve desirable rates of reaction. For multiple substitutions, 
protonic acid has to be used. Iodine is the least reactive halogen in aromatic substitution. In 
this case, an oxidizing agent has to be used for halogenation with I2. [17, 18] 
2.5.1.1. Bromination 
Bromination reaction is carried out with different catalysts. As a catalyst, the most common 
substitute used is Lewis acid (FeBr3). [19] In addition, protonic acids (HOBr, HNO3) or N-
bromo amides (especially N-bromosuccimidine and tetraalkylammonium polyhalides) can be 
used. [15] 
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Scheme 4. Lewis acid catalysed bromination mechanism. 
2.6. Suzuki coupling 
Carbon-carbon bond formation methods are very important reactions that allow us to build 
molecules that are more complex from simple precursors. For a long time, there were 
reactions for the formation of carbon-carbon bonds between saturated sp
3
 atoms but no simple 
method to create a bond between unsaturated groups (vinyl, aryl etc.). [20] 
In this field, Suzuki (also called Suzuki-Miyaura) coupling reaction using boronic acid and 
halide compounds as coupling partners catalysed with palladium(0) complex, is one of the 
most efficient and easiest method for formation of a carbon-carbon bond between unsaturated 
compounds. Even though there are other coupling methods, such as Kharash coupling, 
Negishi coupling, Stille coupling, the Suzuki coupling has proven to be the most favoured. 
[21] 
The Suzuki coupling offers several advantages compared to other methods. It has mild 
reaction conditions and is unaffected of the presence of water. The reaction also can be 
carried out with a broad range of functional groups; the inorganic by-products are non-toxic 
and easily removed, making it suitable also for industrial processes. [22] 
2.7. N- and O-alkylation reaction 
The N-alkylation of heterocyclic compounds bearing an acidic hydrogen atom attached to the 
nitrogen is usually done by the treatment of a suitable base followed by adding an alkylating 
agent (such as alkyl halides). [23] Usually, strong bases (KH, NaH, KOH, sodium amide etc.) 
are used for such kind of reactions. For cyclic N-alkylation, the use of phase transfer catalysts 
is reported, but there is literature available about alkylation of heterocyclic compounds with 
alkyl halides in basic media. [24] 
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Non-selective alkylation of cyclic amides is described to be carried out with anorganic bases, 
such as LiCO3 or LiOH, using alkyl halides as alkylating reagent. With that method, the 
outcome is a mixture of O- and N-akylatated products. For O-selective alkylation, the 
carboxylic oxygen is substituted with chlorine. [25]  
2.8. Solid phase peptide synthesis (SPPS) 
The solid phase peptide synthesis (SPPS) method was first described in the year 1963 by R. 
B. Merrifield. Today, the SPPS is a widely used synthesis method. [26] 
In SPPS, the synthesis is carried out on a solid support, called resin. On the resin there are 
functional groups, which are reaction centres for the first amino acids coupling to the resin. 
[26] 
Peptide synthesis can be performed from N→C terminus of peptide chain or the other way 
around. Since carboxylic group activation on the resin is harder, synthesis from the amino 
terminus is more common. [26] 
SPPS methods also differ for the protecting group used on the amino group. Two main 
protecting groups in use are Boc and Fmoc (Figure 3). The Boc group is removed with strong 
acids (usually trifluoroacetic acid). The Fmoc protecting group is removable with soft bases, 
such as piperidine, so the Fmoc method is more commonly used. In the Fmoc-method, side 
chains are often protected with Boc and other acid labile protecting group, which can be 
removed together with the final cleavage of the peptide sequence from the resin. It is usually 
done with trifluoroacetic acid. The fact that we can use different substances to remove 
protecting groups makes the protecting groups orthogonal. [27]  
             
Figure 3. A – Boc protecting group, B – Fmoc protecting group 
 15 
 
3. Experimental 
3.1. Equipment and reagents 
Purification of the conjugates was performed by Gerda Raidaru on a Shimadzu Prominence 
LC solution HPLC system with a SPD M20A diode array detector and a Phenomenex Gemini 
C18 5 μm column protected by a 5 μm Gemini guard column. Mass spectra were measured by 
Gerda Raidaru on a Shimadzu LCMS-2020 (ESI-MS) in positive ion mode and by Erki 
Enkvist on Applied Biosystems Voyager DE-Pro (MALDI-TOF). NMR data were recorded 
on a Bruker Avance III HD (16.4 T). 
Bromo-esters, benzimidazole, ethyl-3-bromonicotinate and 2-amino-4-methoxycarbonyl 
phenylboronic acid hydrochloride were purchased from ABCR GmbH & Co. KG, dimethyl 
formamide was purchased from Acros Organics, TFA was purchased from Scharlau, and 
triisopropylsilane was purchased from Sigma-Aldrich. Fmoc protected amino acids were 
puschased from Advanced Chemtech, resins used in SPPS were purchased from 
NovaBiochem.  
3.2. Methods 
3.2.1. Synthesis of 4,5,6,7-tetrabromobenzimidazole (TBBI) 
3 ml of Br2 was added drop wise to 590 mg (5 mmol) of benzimidazole in 15 ml concentrated 
HNO3. The solution was refluxed until the reaction completed. The reaction was monitored 
with a MALDI-TOF mass-spectrometer. After cooling of the solution, the precipitate was 
collected by filtration, washed with Na2S2O3 and crystallized in EtOH [10]. The precipitate 
was dried and yielded to 1.46 g (3.36 mmol, yield 67%). Mass spectroscopy gave m/z 
M=435.05 (theoretical for TBBI=434.73).  
 
Scheme 5. Synthesis of TBBI. 
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3.2.3. Synthesis of methyl-8-bromooctanoate 
1.5 ml MeOH was added to 539.9 mg (2.42 mmol) of 8-bromooctanoic acid. Catalytic amount 
of concentrated H2SO4 was added. The solution was stirred at 30 ºC overnight. The thin layer 
chromatography (TLC) (eluent 10:1 chloroform/methanol) was used to monitor the reaction. 
Iodine was used as developer.  
Methanol was removed, and the product was partitioned in a separatory funnel; Na2CO3 
solution and ethyl acetate were used. Ethyl acetate fraction was collected, and liquid was 
removed by rotatory evaporator. 466.5 mg (1.97 mmol, yield 81%) ester was collected. 
 
Scheme 6. Estrification of 8-bromooctanoic acid. 
3.2.4. Alkylation of TBBI 
TBBI (115 mg, 0.26 mmol) and sodium hydride NaH (11.3 mg, ca 0.28 mmol, 60% 
suspension in oil) were dissolved in 3 ml of dimehtylformamide (DMF). The solution was 
mixed at room temperature for 30-60 minutes. Then methyl-8-bromo-octanoate (182 mg, 
0.77 mmol) was added to the reaction mixture was stirred overnight at 50 ºC. TLC (eluent 
20:1 chloroform/methanol) was used for monitoring of the reaction.  
The product was partitioned in a separatory funnel using water and ethyl acetate as solvents. 
Ethyl acetate layer was collected, and the product was first dried in a rotatory evaporator and 
then freeze dried overnight. Additionally, column chromatography was used to purify the 
product (eluent 20:1 chloroform/methanol).  
Scheme 7. Alkylation of TBBI. 
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3.2.5. Hydrolysis of TBBI ester. 
For hydrolysis, 4 ml H2O, three pellets of KOH and 0.5 ml of EtOH was added to the purified 
ester. The reaction mixture was stirred until all of the ester was dissolved, and then heated for 
30-60 minutes at 50 ºC. The reaction was monitored with TLC (eluent 20:1 
chloroform/methanol). The residue was partitioned between ethyl acetate and KHSO4 
solution. Ethyl acetate was collected, and the product was dried with rotatory evaporator to 
yield 8-(4,5,6,7-tetrabromo-1H-benzimidazol-1-yl)octanoic acid (95 mg, 62% over two steps). 
 
Scheme 8. Hydrolysis of alkylated TBBI ester 
3.2.6. Suzuki coupling 
For Suzuki coupling reaction 150 μl ethyl-3-bromonicotinate (1.1 mmol), 232 mg 2-amino-4-
methoxycarbonyl-phenylboronic acid hydrochloride (1 mmol), 40.6 mg PdCl2(dppf) (0.06 
mmol) and 365 mg sodium acetate (4.4 mmol) were dissolved in 2 ml of DMF. Flask was 
filled with nitrogen. Reaction mixture was stirred for 12 hours at 125 ºC. After 12h, the 
reaction mixture was cooled to room temperature and 30 ml of water was added. A brown 
precipitate formed (compound 1) [25]. Precipitate was washed with water twice and dried in 
freeze drier overnight. 
CH3
O
O
Br
N
CH3O
O
NH2
OH
OH
B
CH3
O
O
O
N
NH
+
Pd
DMF
1
 
Scheme 9. Suzuki coupling 
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3.2.7. Alkylation of compound 1 
Compound 1 (32 mg, 0.13 mmol) and NaH (22.8 mg, ca 0.5 mmol) were dissolved in 1 ml of 
DMF. The solution was mixed at room temperature for 60 minutes and then 
70 μl methyl-9-bromononanoate was added. The reaction mixture was stirred overnight at 
50 ºC. Reaction was monitored with TLC (eluent 9:1 chloroform/methanol). The product was 
partitioned between ethyl acetate and water. Organic layer was collected and dried with 
rotatory evaporator. Reaction resulted with O-alkylated and N-alkylated isomers (compounds 
2a and 2b). 
CH3
O
O
O
N
NH
CH3
O
O
O
CH3
O O
N
N
Br-(CH2)8COOCH3
NaH, DMF
O
CH3
O O
N
N
CH3
O
O
+
2a
2b
 
Scheme 10. Alkylation of compound 1 
3.2.8. Hydrolysis of compounds 2a and 2b 
For hydrolysis, 1.5 ml water and two KOH pellets were added to compounds 2a and 2b. 
Reaction mixture was stirred for 60 minutes at 50 ºC. Reaction was monitored with TLC 
(eluent 9:1 chloroform/methanol). After 1 hour, the mixture was cooled down to room 
temperature. The solution was poured to a 15 ml tube and centrifuged. The liquid was poured 
into a 50 ml tube, and KHSO4 solution was added to the reaction mixture. Reducing pH 
caused precipitation (mixture of compounds 3a and 3b). Precipitate was centrifuged, washed 
with water twice and evaporated to dryness. 
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Scheme 11. Hydrolysis of compounds 2a and 2b 
Since the compound has not been characterized before, then the isomers were separated and 
purified with HPLC and both isomers were analysed with NMR spectroscopy. Compund 2a: 
1
H  NMR (DMSO-d6, 700MHz): δ: 1.31 (m, 4H), 1.40 (kv, J=7.0, 2H), 1.45 (m, 4H), 1.90 
(kv, J=7.0, 2H), 2.19 (t, J=7.0, 2H), 4.62 (t, J=6.3, 2H), 8.09 (dd, J=8.4, J=1.4, 1H), 8.14 (dd, 
J=5.6, J=0.7, 1H), 8.36 (d, J=2.1,1H), 8.94 (d, J=8.4, 1H), 8.97 (d, J=4.9, 1H), 10.20 (s, 1H). 
13
C NMR (DMSO-d6, 700MHz): δ 24.5, 25.6, 28.2, 28.5, 28.71, 28.74, 33.7, 66.7, 116.9, 
123.2, 123.51, 124.2, 125.3, 127.7, 128.7, 131.8, 142.6, 147.5, 148.1, 157.9, 167.0, 171.6. 
Compound 2b: 
1
H NMR (DMSO-d6, 700MHz): δ 1.25 (m, 4H), 1.36 (kv, J=7.0, 2H), 1.42 
(kv, J=7.7, 2H), 1.48 (kv, J=7.0, 2H), 1.71 (kv, J=7.7, 2H), 2.19 (t, J=8.4, 2H), 4.38 (t, J=7.7, 
2H), 7.91 (dd, J=8.4, J=1.4, 1H), 8.08 (d, J=1.4, 1H), 8.19 (dd, J=4.9, J=0.7, 1H), 8.82 (d, 
J=8.4, 1H), 8.89 (d, J=4.9, 1H), 9.97 (s, 1H). 
13
C NMR (DMSO-d6, 700MHz): δ 24.5, 26.3, 
26.7, 28.5, 28.7 (2C), 33.7, 42.3, 116.3, 120.2, 120.4, 123.1, 124.2, 126.8, 130.5, 132.6, 
136.9, 146.9, 149.0, 159.2, 166.8, 174.6. 
NMR spectrums are presented in the Appendix 1. 
3.2.9 Optimization of compound 1 alkylation reaction 
The aim of the optimization was to increase the reaction yield and to increase the isomer ratio 
toward compound 2a. 
In the first step of optimisation temperature, base and solvent were varied. Every reaction was 
held in a different eppendorf tube. Reagents were weighed into tubes (NaH or 
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potassium tert-butoxide (KOtBu) was used as a base), solvent (DMF or dimethyl sulfoxide 
(DMSO)) was added, and the reaction mixtures were left at room temperature for 30 minutes. 
Then 3 μl of ethyl-9-bromononanoate and 30 μl of DMF or DMSO were added. Reactions 
were carried out overnight at room temperature or at 50 ºC. On the next day reactions were 
checked with TLC. After reactions were completed, reaction mixtures were dried in a freeze 
drier. 
For hydrolysis, one KOH pellet was dissolved in 1 ml of deionised water. 30 μl of that 
solution was added to each reaction tube. In the first 2 hours the reaction was held at room 
temperature, and then incubated at 50 ºC for 2 hours. All tubes were centrifuged to discard the 
by-product of the Suzuki reaction. After centrifugation the solvent from each reaction mixture 
was carried to a new eppendorf tube. To each mixture 100 μl KHSO4 solution was added. 
Precipitate was centrifuged; solvent was removed. Precipitate was washed with water twice to 
get rid of salts and dried with a freeze drier. All the reaction mixtures were then analysed with 
HPLC. Synthesis with KOtBu in DMF at room temperature showed the best result. 
In the second step of optimisation cations, base and temperature were changed. The alkylation 
reaction was held as described in the first step, but in one reaction LiCO3 was used as a base 
and in two reactions tetramethylammonium chloride (TMACl) or tetrabutylammonium 
bromide (TBABr) was used as a cation source. To see the effect of temperature, a reaction 
where KOtBu was used was carried out at 0 ºC. After alkylation, hydrolysis reaction was 
performed as described in the first step. Again, all products were analysed with HPLC. 
3.2.10. Peptide fragment synthesis 
For peptide fragment synthesis the traditional Fmoc solid phase peptide synthesis (Fmoc-
SPPS) method was used [27]. DMF was used as a solvent. Before synthesis resin was swolen 
for about 45 minutes.  
For the activation of an amino acid (3 equiv.) HBTU (2.85 equiv.), HOBt (2.85 equiv.) and N-
methylmorpholine (NMM, 10 equiv.) were used. Amino acid and activators were dissolved, 
transferred to a 5 ml tube and mixed properly. Then the solution with activated amino acid 
was transferred to resin, and the reaction flask was put on a shaker for 60-90 minutes. After 
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every acylation reaction, the resin was washed 5 times with DMF and the completion of the 
reaction was controlled with Kaiser test. 
For Kaiser test solution A (5% ninhydrin in ethanol) and B (80% phenol in ethanol) were 
used. Some resin beads were transferred from the reaction flask to the eppendorf tube, and 50 
μl of solution A and B were added to the beads. The mixture was heated for 5-10 minutes, and 
if many resin beads changed their colour to blue, the reaction was repeated. 
If the reaction was successful, then for adding next amino acid, the Fmoc protecting group 
had to be removed. The removal of Fmoc group was done with 20% piperidine solution in 
DMF for 3+17 minutes, and then resin was washed with DMF 5 times. 
To measure the loading (amount of activated groups) of resin, Fmoc cleaving and washing 
solutions were collected. With UV-Vis spectrometer, the spectrum of the solution was 
measured, and the Fmoc concentration was calculated with Lambert-Beer law (λ=290 nm, 
ε=5352 l/mol*cm).  
3.2.11. Conjugate synthesis 
TBBI acid and the mixture of 3a and 3b were added to the peptide by using the SPPS method. 
Using resin with previously synthesised amino acid sequence, solution of TBBI or mixture of 
3a and 3b (2 equiv.), HBTU (1.9 equiv.), HOBt (1.9 equiv.) and NMM (6 equiv.) were added 
to the resin. Synthesis was carried out for 2-3 hours and the quantity of acylation was 
controlled with Kaiser test. 
Before cleaving, resin was washed 5 times with three different solvents: DMF, isopropyl 
alcohol and dichloroethane. After washing, the resin was dried with vacuum. Solution of 
TFA/H2O/triisopropylsilane (ratio 90:5:5) was used for cleaving. The cleaving reaction was 
carried out for 2 hours. The cleaving solution was poured in to diethyl ether, where it 
precipitated. The precipitate was centrifuged, washed with diethyl ether twice and dried. 
Purification and analyses were done with reverse phase HPLC-ESI-MS. 
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4. Results and discussions 
4.1. Selecting structural elements for inhibitors 
For the ATP-competitive part of the bisubstrate inhibitor, two different fragments were 
chosen. TBBI is described in the literature as a selective ATP-competitive inhibitor for CK2 
[10]. Compounds 3a and 3b were based on a high affinity ATP-competitive inhibitor CX-
4945 [25], which is the first CK2 inhibitor that is in the clinical trials. Those fragments were 
chosen because for synthesising bisubstrate inhibitors, there has to be a functional group, to 
attach the fragment to the peptide part. Both fragments were suitable for adding a linker with 
a carboxylic group through alkylation reaction, and, for those reasons, these two inhibitors 
were good candidates for ATP-competitive part.  
The choice of amino acids used in the peptide part of the bisubstrate inhibitor was based on 
the acidophilic characteristics of CK2. Aspartic acid was chosen because it was the acidic 
amino acid with the lowest molecular mass. To define the effect of the length and isomeric 
difference of the peptide part to the affinity, both characteristics were varied. To determine 
the importance of distinctly positioned aspartic acid in the peptide part, the sequence was 
altered with hydrophobic amino acid. 
The length of the linker was varied to characterise its effect to the affinity of the inhibitor. 
The effects of different variations are presented in the section 4.7. 
4.2. Synthesis of TBBI 
Synthesis of TBBI was based on the protocol described in the literature [9]. The time of the 
reaction was changed because in the protocol reaction mixture was heated under reflux for 
24h, but in reality the reaction took place around 3-10 days. It was monitored with 
MALDI-TOF MS, and the reaction was stopped when the compound with four brominations 
was the main product. The reaction was conducted three times, and the yield varied from 63% 
to 67%. 
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4.3. Synthesis of compound 1 
Synthesis of compound 1 was based on the protocol described in the literature [25]. Again, the 
purification of the product was not as easy as described in the publication. Reaction had a by-
product, which was soluble in the same solvents as the product. That is why yield was not 
calculated. By-product from Suzuki coupling reaction appeared in all the following reactions. 
4.4. Alkylation of TBBI and compound 1 
In the first stage NaH was added to the TBBI or compound 1 solution in DMF to 
dehydrogenate the cyclic nitrogen and to activate the alkylation site.  
In the second stage several ester of ω-bromo carboxylic acid with different lengths were 
added to the solution and alkylation was carried out. Alkylation of compound 1 resulted with 
two isomers: O- and N-alkylated derivates. 
A separatory funnel was used to remove the water soluble by-products (for example, NaBr). 
Ethyl acetate was used as the second solvent, where the products were soluble. Ethyl acetate 
fraction was collected and dried with a rotatory evaporator. Since bromo-esters used in the 
synthesis were also hydrophobic and dissolved in ethyl acetate, in some cases column 
chromatography was used for additional purification. Whereas the column chromatography is 
time consuming and the bromo-ester did not disturb significantly the next steps of synthesis, 
the additional purification step was not carried out after every alkylation reaction. The 
isomers from the alkylation of the compound 1 were not separated after the reaction. The 
separation of the isomers was done with HPLC for the final conjugates. 
In the article [25] the alkylation was carried out through chloride substitution of the amidic 
oxygen using POCl3. This method was not used in this work because of unidentified reasons, 
the reaction did not take place as it was described in the publication. 
4.5. Base catalysed hydrolysis of esters 
Hydrolysis of the products of the alkylation reaction was carried out with a solution of KOH. 
Reaction was monitored with TLC and took place in 30-60 minutes. In that stage most of the 
by-product from CX-derivate synthesis was removed because it did not dissolved in aqueous 
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solution. The reaction was fast, and the product was easy to collect. Since base catalysis 
worked easily, the method was used throughout all the hydrolysis. 
4.6. Optimisation of the synthesis of the compound 3a 
Since the ratio of alkylation was toward compound 3b, but measurements showed that 
inhibitors with compound 3a had a higher affinity, the alkylation reaction needed to be 
optimized.  
The next two tables show conditions used for optimisation of the alkylation reaction.  
Table 1. Results of the first optimisation step 
Reaction 
number 
Compund 
1 mass 
(mg) 
Used base 
and it’s 
mass (mg) 
Solvent Temperature 
(ºC) 
Ratio between 
N- and O-
alkylation 
Reaction 
depth* 
1. 0.22 NaH, 2.12 DMF r.t. O-alkylated 
isomer was not 
registered 
19% 
2. 0.20 NaH, 2.01 DMF 50 1.7:1 24% 
3. 0.34 NaH, 2.45 DMSO 50 4.6:1 69% 
4. 0.60 KOtBu, 
1.16 
DMF r.t 0.8:1 75% 
5. 0.71 KOtBu, 
1.70 
DMF 50 1.9:1 51% 
6. 0.67 KOtBu, 
1.20 
DMSO 50 3.2:1 58% 
* - calculation was based on the peak areas of HPLC spectrum 
After the first stage, it showed that reaction condition nr 4 gave the best results. Reactions 
using NaH gave lower product yields compared to the reactions with KOtBu. There was also 
a difference between using DMF or DMSO as the solvent. Reactions with DMSO gave more 
unidentified by-products than reactions using DMF as the solvent. 
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Since different cation (KOtBu) gave better results than the one usually used, in the second 
step the cation was varied to see the effect of its size and characteristics (reactions 8-10). 
Reaction at room temperature gave a better alkylation ratio toward O-alkylation than reactions 
carried out at 50 ºC. Therefore reaction at lower temperature (0 ºC) was carried through to see 
the temperature effect on the alkylation ratio (reaction 7) 
Table 2. Results of the second optimisation step, TMACl – tetramethylammoniumchloride, 
TBABr – tetrabutylammoniumbromide 
Reaction 
number 
Compound 
1 mass 
(mg) 
Used base 
and it’s 
mass (mg) 
Cation 
source 
and mass 
(mg) 
Temperature 
(ºC) 
Ratio 
between 
N- and O-
alkylation 
Reaction 
depth* 
7. 0.65 KOtBu, 
0.50 
- 0 3.7:1 37% 
8. 0.80 Li2CO3, 
0.45 
- r.t. Reaction 
did not 
take place 
- 
9. 0.72 KOtBu 0.45 TMACl, 
1.20 
r.t. 6.1:1 21% 
10. 0.80 KOtBu 0.48 TBABr, 
2.94 
r.t. 4.2:1 63% 
* - calculation was based on the peak areas of HPLC spectrum 
Li2CO3, TMACl and TBABr were used to see the effect of different cation. Lithium carbonate 
was probably too weak base to dehydrogenate the amide bond of compound 1. TMACl and 
TBABr were used to see the steric effect of the cation. Both reactions took place, but neither 
the yield nor the ratio toward O-alkylation improved. 
Among the 10 different alkylation reaction conditions, reaction condition nr 4 gave the best 
result. 
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4.7. Synthesised inhibitors 
Altogether 25 new inhibitors were synthesised. ATP competitive part, length and composition 
of peptide part and linker were varied. Composition and biological activity of inhibitors are 
presented in Table 3. Full structures of inhibitors and their molecular weights are presented in 
Appendix 2. 
Table 3. List of new inhibitors. All KD values are measured and calculated by Siiri Saaver, 
using fluorescent anisotropy. [13] 
Inhibitor code Composition KD (st. dev), nM 
ARC-1506 TBBI-(CH2)7-CO-L-Asp 43.4 (6.9) 
ARC-1507 TBBI-(CH2)7-CO-(L-Asp)2 26.8 (8.2) 
ARC-1508 TBBI-(CH2)7-CO-(L-Asp)3 4.64 (3.15) 
ARC-1518 TBBI-(CH2)7-CO-(L-Asp)4 2.21 (0.20) 
ARC-1519 TBBI-(CH2)7-CO-(L-Asp)5 1.72 (1.09) 
ARC-1509 TBBI-(CH2)7-CO-(L-Asp)6 0.55 (0.40) 
ARC-1510 TBBI-(CH2)9-CO-(L-Asp)3 6.99 (4.46) 
ARC-1511 TBBI-(CH2)9-CO-Gly-(L-Asp)3 9.58 (6.52) 
ARC-1512 TBBI-(CH2)9-CO-ABut-(L-Asp)3 12.0 (6.35) 
ARC-1514 TBBI-(CH2)9-CO-(L-Asp)5 1.73 (1.19) 
ARC-1515 TBBI-(CH2)9-CO-(L-Asp)6 0.72 (0.42) 
ARC-1424O CX-(CH2)8-CO-(L-Asp)6-L-Lys Undefined 
ARC-1513O CX-(CH2)8-CO-(L-Asp)6-L-Lys-PF555 0.0098 (0.0018) 
ARC-1520O CX-(CH2)8-CO-(L-Asp)5-L-Leu-L-Lys 0.083 (0.028) 
ARC-1520N CX-(CH2)8-CO-(L-Asp)5-L-Leu-L-Lys 0.95 (0.004) 
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ARC-1521O CX-(CH2)8-CO-(L-Asp)4-L-Leu-L-Asp-L-Lys 0.11 (0.02) 
ARC-1521N CX-(CH2)8-CO-(L-Asp)4-L-Leu-L-Asp-L-Lys 1.51 (0.11) 
ARC-1522O CX-(CH2)8-CO-(L-Asp)3-L-Leu-(L-Asp)2-L-Lys 0.15 (0.03) 
ARC-1522N CX-(CH2)8-CO-(L-Asp)3-L-Leu-(L-Asp)2-L-Lys 1.14 (0.06) 
ARC-1523O CX-(CH2)8-CO-(L-Asp)2-L-Leu-(L-Asp)3-L-Lys 0.18 (0.041) 
ARC-1523N CX-(CH2)8-CO-(L-Asp)2-L-Leu-(L-Asp)3-L-Lys 1.42 (0.13) 
ARC-1524O CX-(CH2)8-CO-L-Asp-L-Leu-(L-Asp)4-L-Lys 0.37 (0.11) 
ARC-1524N CX-(CH2)8-CO-L-Asp-L-Leu-(L-Asp)4-L-Lys 0.85 (0.38) 
ARC-1525O CX-(CH2)8-CO-L-Leu-(L-Asp)5-L-Lys 0.24 (0.14) 
ARC-1525N CX-(CH2)8-CO-L-Leu-(L-Asp)5-L-Lys 1.25 (0.07) 
To find the effect of the length of the peptide part compounds ARC-1506 to ARC-1509, 
ARC-1518 and ARC-1519 were prepared. The length of peptide part was varied by applying 
increasing the number of aspartic acids. As suspected, the number of aspartic acids does affect 
the affinity of the inhibitor. Inhibitors with longer peptide parts have higher affinity toward 
CK2. The effect shows that using smaller molecular weight bisubstrate inhibitor results in 
lower affinity. 
In inhibitors ARC-1510 to ARC-1512, ARC-1514, ARC-1515 the length of the linker was 
varied to see the effect of different linker characteristics. For ARC-1510, ARC-1514 and 
ARC-1515 the length of the linker was only extended. Results showed that longer linkers do 
not increase the affinity of these compounds. The results are comparable with the inhibitors, 
which have the same number of aspartic acids in their peptide part, but different linker. For 
compounds ARC-1511 and ARC-1512 the length was changed. From those results it was 
concluded that the octanoic linker already has an optimal length for that type of bisubstrate 
inhibitors. 
Compound 3a was used as the ATP-competitive fragment for ARC-1424, ARC-1513 and 
ARC-1520 to ARC-1525. Since CX-4945 was reported as a high affinity and selectivity 
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inhibitor for CK2, a fragment of it was used to reach higher affinities with bisubstrate 
inhibitors. As the results in Table 3 shows, the prediction was right and bisubstrate inhibitors 
with compound 3a gave higher affinities. The affinity of ARC-1424O was not measurable 
with probe ARC-1504 [13] because of its too high affinity and a new fluorescent probe ARC-
1513O was synthesised to solve this issue. The fluorescent probe reached the affinity around 
10 pM. Inhibitors for CK2 with such high affinities have not been reported before. Using 
compound 1 as the ATP-competitive part, the conjugate synthesis resulted also with N-
alkylated isomer. Compared to 1424O, the isomer 1424N had about 10 times lower affinity. 
For that reason, the N-alkylated isomers are not presented in the table.  
From ARC-1520 to ARC-1525, peptide part was systematically varied by using scanning 
with leucine to see the importance of the position of different aspartic acids in the peptide 
chain. Leucine was chosen because of its abundance in the positions near to the 
phosphorylation site (n-4 to n+10) of protein substrates of CK2. Results of the data analysis 
are presented in Appendix 3. Analysis was based on the publication [28]. 
From the results presented in the Table 3, it can be concluded that the first and second aspartic 
acids in the chain have greater importance, when binding to the enzyme, because the affinities 
of the inhibitors with those positions substituted with leucine were most affected compared to 
the ARC-1513O. Also it seems that the last three aspartic acids contribute equally to the 
inhibitor binding to the enzyme. 
 29 
 
5. Summary 
Phosphorylation of proteins is an important regulatory modification to the processes in cell 
functioning. Enzymes that catalyse this post-translational modification are called protein 
kinases. Increased activity of protein kinases, such as CK2, is related to different diseases, 
including various types of cancers. For that matter there is a need for selective and affine 
inhibitors for protein kinases. 
Herein, 25 new bisubstrate inhibitors of CK2 were synthesised and characterised.  
The aim of the study was to optimize all three parts of the bisubstrate inhibitor to result in 
highly selective and affine compounds for CK2. Two different ATP-competitive parts were 
used in the inhibitors; whereas 5-oxo-5,6-dihydrobenzo[c][2,6]naphthyridine-8-carboxylic 
acid was a fragment of CK2 inhibitor CX-4945 in clinical trials. Inhibitors with this fragment 
gave the best results, reaching affinities around 10 pM. The length of the linker was varied to 
find the optimal positioning of the interacting fragments. Many peptide part modifications 
were done, including variation of the length of the peptide part and, using leucine scanning, 
determination of the contribution of differently positioned amino acids. Crystallographic 
studies are performed on the base of the collaboration to achieve data about the peptide part 
interactions with CK2.  
The future prospect is to improve CK2 bisubstrate inhibitors, develop and research cell-
penetrating CK2 bisubstrate inhibitors and also continue to develop bisubstrate inhibitors that 
could help the study of the interactions between CK2 and its peptide substrates.  
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Kõrgafiinsete inhibiitorite süntees proteiinkinaasile CK2 
Jürgen Vahter 
Kokkuvõte 
Fosforüülimine on oluline posttranslatoorne modifikatsioon, mille kaudu reguleeritakse 
paljusid protsesse raku elutsüklis. Neid reaktsioone katalüüsivaid ensüüme nimetatakse 
proteiinkinaasideks. Proteiinkinaaside, seal hulgas CK2, suurenenud aktiivsus seostatakse 
mitmete haigustega nagu näiteks erinevate vähi tüüpidega. 
Töö käigus sünteesiti ja iseloomustati 25 uut CK2 bisubstraatset inhibiitorit. 
Töö käigus varieeriti bisubstraatsete inhibiitorite kõiki kolme osa (ATP-konkurentset 
fragmenti, peptiidsubstraatset osa, neid ühendavat lüli) ning optimeeriti kasutatud sünteesi 
meetodeid. ATP-konkureeriva fragmendina kasutati kahte erinevat varem kirjanduses 
teadaolevat inhibiitorit, millest üks on hetkel kliinilistes katsetustes olev CK2 inhibiitori CX-
4945 fragment. CX-4945 fragmendiga inhibiitorid andsid häid tulemusi, parima ühendi 
afiinsus olid 10 pM.  Ühendava lüli pikkust varieeriti, et leida sellele optimaalne suurus 
uuritava ensüümi jaoks. Modifitseeriti ka peptiidset osa, muutes selle pikkust ning koostist, et 
mõista erinevates asendites olevate aminohapete olulisust. Ühendite kristallograafilised 
uuringud toimuvad koostöös Kölni Ülikooliga. 
Tulevikus jätkatakse CK2 bisubstraatsete inhibiitorite edasiarendust kõrgema afiinsusega 
ühendite sünteesimiseks. Lisaks kavatsetakse kasutada modifikatsioone, mis muudaks neid 
aineid rakku sisenevateks. Samuti jätkub töö leidmaks inhibiitoreid, mida õnnestuks koos 
CK2-ga kristallida nii, et peptiidse fragmendi elektrontihedus oleks mõõdetav. 
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Appendices 
APPENDIX 1. NMR spectrums of compounds 3a and 3b 
Compound 3b 
13
C NMR spectrum 
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C NMR spectrum 
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APPENDIX 2. Structures and molecular weights (m.w.) of new ARC-type inhibitors 
ARC 
code 
Structure M.w. 
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COOH
O
NH
NH
O
COOH
COOH
COOH
O
NH
O
NH
NH
O
Br
Br
Br
Br
N
N
1265.5 
 40 
 
 
ARC-
1510 OH
O
COOH
COOH
COOH
O
NH
O
NH
NH
O
Br
Br
Br
Br
N
N
 
948.2 
ARC-
1511 
O
Br
Br
Br
Br
N
N
O
NH OH
O
COOH
COOH
COOH
O
NH
O
NH
NH
 
1005.3 
ARC-
1512 
O
Br
Br
Br
Br
N
N
O
NH OH
O
COOH
COOH
COOH
O
NH
O
NH
NH
 
1033.4 
ARC-
1514 
O
COOH
OH
COOH
O
NH
NH
O
COOH
COOH
COOH
O
NH
O
NH
NH
O
Br
Br
Br
Br
N
N
 
1178.4 
ARC-
1515 
COOH
O
OH
O
COOH
NH
COOH
O
NH
NH
O
COOH
COOH
COOH
O
NH
O
NH
NH
O
Br
Br
Br
Br
N
N
 
1293.5 
ARC-
1424O 
OH
NH
NH
O
COOH
COOH
COOH
O
NH
O
NH
O
O
OOH
N
N O
COOH
COOH
COOH
O
NH
O
NH
O
NH
NH2
 
1215.1 
 41 
 
ARC-
1424N 
OH
NH
NH
O
COOH
COOH
COOH
O
NH
O
NH
O O
COOH
COOH
COOH
O
NH
O
NH
O
NH
NH2
O
O OH
N
N
 
1215.1 
ARC-
1513O 
OH
NH
NH
O
COOH
COOH
COOH
O
NH
O
NH
O
O
OOH
N
N O
COOH
COOH
COOH
O
NH
O
NH
O
NH
NH
N
S
O
O
OH
N
S
O
O
OH
O
 
1815.9 
ARC-
1513N 
N
S
O
O
OH
N
S
O
O
OH
O
OH
NH
NH
O
COOH
COOH
COOH
O
NH
O
NH
O O
COOH
COOH
COOH
O
NH
O
NH
O
NH
NH
O
OOH
N
N
 
1815.9 
ARC-
1520O 
OH
NH
NH
O
COOH
COOH
COOH
O
NH
O
NH
O O
COOH
COOH
O
NH
O
NH
O
NH
NH2
O
O OH
N
N
 
1213.2 
 42 
 
ARC-
1520N 
OH
NH
NH
O
COOH
COOH
COOH
O
NH
O
NH
O O
COOH
COOH
O
NH
O
NH
O
NH
NH2
O
O OH
N
N
 
1213.2 
ARC-
1521O 
OH
NH
NH
O
COOH
COOH
COOH
O
NH
O
NH
O O
COOHCOOH
O
NH
O
NH
O
NH
NH2
O
O OH
N
N
 
1213.2 
ARC-
1521N 
OH
NH
NH
O
COOH
COOH
COOH
O
NH
O
NH
O O
COOHCOOH
O
NH
O
NH
O
NH
NH2
O
O OH
N
N
 
1213.2 
ARC-
1522O 
OH
NH
NH
O
COOH
COOH
COOH
O
NH
O
NH
O O
COOH
COOH
O
NH
O
NH
O
NH
NH2
O
O OH
N
N
 
1213.2 
ARC-
1522N 
OH
NH
NH
O
COOH
COOH
COOH
O
NH
O
NH
O O
COOH
COOH
O
NH
O
NH
O
NH
NH2
O
O OH
N
N
 
1213.2 
 43 
 
ARC-
1523O 
OH
NH
NH
O
COOH
COOH
O
NH
O
NH
O O
COOH
COOH
COOH
O
NH
O
NH
O
NH
NH2
O
O OH
N
N
 
1213.2 
ARC-
1523N 
O
O OH
N
N
OH
NH
NH
O
COOH
COOH
O
NH
O
NH
O O
COOH
COOH
COOH
O
NH
O
NH
O
NH
NH2
 
1213.2 
ARC-
1524O 
OH
NH
NH
O
COOHCOOH
O
NH
O
NH
O O
COOH
COOH
COOH
O
NH
O
NH
O
NH
NH2
O
O OH
N
N
 
1213.2 
ARC-
1524N 
OH
NH
NH
O
COOHCOOH
O
NH
O
NH
O O
COOH
COOH
COOH
O
NH
O
NH
O
NH
NH2
O
O OH
N
N
 
1213.2 
ARC-
1525O 
OH
NH
NH
O
COOH
COOH
O
NH
O
NH
O
O
OOH
N
N O
COOH
COOH
COOH
O
NH
O
NH
O
NH
NH2
 
1213.2 
 44 
 
ARC-
1525N 
OH
NH
NH
O
COOH
COOH
O
NH
O
NH
O O
COOH
COOH
COOH
O
NH
O
NH
O
NH
NH2
O
O OH
N
N
 
1213.2 
 
 45 
 
APPENDIX 3. Data of CK2 protein substrate sequence analysis 
Number of different amino acids (AA) in different position 
 
